J3 Bioscience, Inc. Announces Appointment of New Director to Board
Salt Lake City, UT – October 1, 2024.
J3 Bioscience, Inc., a commercialization stage women’s health medical device company, today announced the appointment of Dr. Sheryl A. Kingsberg to its Board of Directors.
Dr. Kingsberg is the chief of behavioral medicine at MacDonald Women’s Hospital/University Hospitals Cleveland Medical Center and Professor in Reproductive Biology, Psychiatry and Urology at Case Western Reserve University. Her areas of clinical specialization include sexual medicine, female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility.
Her primary research interests are in treatments for female sexual disorders and the psychological aspects of infertility and menopause. She has been the principal investigator for several clinical trials for treatments for female sexual disorders and consults for many pharmaceutical companies that are developing investigational drug treatments for sexual problems. She is an Associate Editor for Sexual Medicine Reviews and sits on the editorial boards of the journal Menopause and Climacteric.
Dr. Kingsberg is a Past President of both The Menopause Society and The International Society for the Study of Women’s Sexual Health.
“We are very honored to add Dr. Sheryl A. Kingsberg to our Board and continue to augment the Company with such high-level experts to support the endeavors of J3 Bioscience,” said Dr. R. Tyler McCabe, President and CEO of the Company. “Dr. Kingsberg will bring important expertise to the Board including sexual medicine, aging and sexuality, menopause management, female sexual dysfunction, and various other relevant aspects of women’s health. She currently is at University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine. In addition to her 131 peer-reviewed publications, she also has authored or co-authored the following three relevant manuscripts including: Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey (2013), The Women’s EMPOWER Survey: Identifying Women’s Perceptions on Vulvar and Vaginal Atrophy and Its Treatment (2017), and The Women’s EMPOWER Survey: Women’s Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate (2017). We anticipate her contribution to the Board will enhance the Company significantly in several ways,” noted Dr. McCabe.
With the addition of a new director, J3 Bioscience’s Board now consists of ten members with diverse backgrounds and expertise, further strengthening the company’s marketing and strategic oversight.
About J3 Bioscience, Inc.
J3 Bio is a commercialization stage women’s health medical device company. The Company’s lead product, known as the LivRing® (formerly termed VR101), is an FDA cleared (K203377), patented and unique lubricating intravaginal ring (IVR). It is designed to moisturize and lubricate the vagina, enhance the ease and comfort of intimate sexual activity, and supplement the body’s natural lubrication. It contains no hormones/drugs, is long-lasting (7 days each), and self-inserted weekly. It is the only IVR that provides long-lasting controlled-release of a moisturizing lubricant.
CONTACT:
R. Tyler McCabe, PhD
Chief Executive Officer, J3 Bioscience, Inc.
[email protected]
